Navigation Links
OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009
Date:3/11/2009

nts that could be deemed forward-looking statements.

The potential risks and uncertainties associated with forward-looking statements include, among others, the possibility that an agreement with the FDA cannot be reached regarding a clinical trial using pain as the primary endpoint for OGX-011, the timing and costs of clinical trials and regulatory approvals, risks that clinical trials will not be successful or confirm earlier or interim clinical trial results, the Company's need for additional financing, the uncertainty associated with any potential partnering discussions, risks relating to the development, safety and efficacy of therapeutic drugs and potential applications for these products and the risk factors set forth in the Company's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for fiscal year 2008. No assurances can be given that any of the events anticipated by the forward-looking statements will transpire or occur, or that if any of them do transpire or occur, what impact they would have on the results of operations or financial condition of the Company. The Company undertakes no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof.

               Condensed Consolidated Statements of Operations
                               (in thousands)

                                    Three Months Ended        Year Ended
                                       December 31,          December 31,
                                       2008       2007       2008       2007
                                       (unaudited)
    Operating expenses
      Research and development     $  4,198   $  1,060   $  7,819   $  4,135
      General and administrative      1,050        831      3,293      3,540
                                   --------------------  --------------------
    Total oper
'/>"/>
SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
2. Sonus Pharmaceuticals and OncoGenex Technologies to Merge
3. OncoGenex to present at the Needham & Company 7th Annual Biotechnology & Medical Technology Conference
4. OncoGenex increases economic interest in lead cancer drug OGX-011
5. OncoGenex receives completed Special Protocol Assessment for primary registration study of lead drug candidate OGX-011
6. Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today
7. FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals Lead Product Candidate OGX-011
8. OncoGenex Pharmaceuticals announces out-license of TOCOSOL Paclitaxel to Eagle Pharmaceuticals
9. OncoGenex To Present At The BioContact Quebec 2008 Annual Conference
10. OncoGenex Achieves Key Regulatory Milestone for Lead Product Candidate, OGX-011
11. OncoGenex Pharmaceuticals to Release Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... Feb. 26, 2015 /PRNewswire/ - SQI Diagnostics Inc. ("SQI" ... sciences company that develops and commercializes proprietary technologies and ... and operational results for the fiscal first quarter ended ... are in Canadian dollars (CAD), unless otherwise stated. ... win new business from our existing customers and add ...
(Date:2/26/2015)... Fla. , Feb. 26, 2015 DuPont ... growth priorities driven by key research advancements and product ... at today,s Bank of America Merrill Lynch 2015 Global ... the challenge of building grain supplies the last two ... continue at the pace of the last decade, when ...
(Date:2/26/2015)... -- The healthcare landscape is rapidly and radically changing. To ... host its 20 th Anniversary Medical Technologies 2015: ... 10, at the Hilton San Diego Resort and Spa in ... event is a platform for global medical devices, diagnostics, life ... how to succeed in an uncertain future. Participants ...
(Date:2/26/2015)... February 26, 2015 Innovation is ... emerging from unexpected parts of the world and ... From agriculture to manufacturing to health care, disruption ... environmental realities and socio-political trends shake the foundations ... key ingredient for CEOs to survive the next ...
Breaking Biology Technology:SQI Diagnostics Reports First Quarter Financial Results 2SQI Diagnostics Reports First Quarter Financial Results 3SQI Diagnostics Reports First Quarter Financial Results 4SQI Diagnostics Reports First Quarter Financial Results 5SQI Diagnostics Reports First Quarter Financial Results 6DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 2DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 3DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 4DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 5Embrace the Future of Medical Technologies with Frost & Sullivan 2Embrace the Future of Medical Technologies with Frost & Sullivan 3One Million Acts of Innovation Canada Creates Partnership with The Economist Events’ Innovation Forum 2
... NV,(Euronext Brussels: THR), a biotechnology company focused on ... is today issuing a,business update for the nine ... De Haes, CEO of ThromboGenics, commenting on today,s,announcement, ... anticipated. We are now working hard to prepare ...
... 6 AmeriCares has,awarded its annual "Power ... global biotechnology, medical device and specialty pharmaceutical,company. ... Distribution,Management Association,s (HDMA) Annual Leadership Forum in ... award was created by AmeriCares and HDMA ...
... Calif., Nov. 6 ( http://www.amdl.com ),AMDL, Inc. ... with major operations in China and the U.S., ... Douglas MacLellan will present at,Rodman & Renshaw,s Annual ... 2008 at the New York Palace Hotel in ...
Cached Biology Technology:ThromboGenics N.V.: Business Update 2ThromboGenics N.V.: Business Update 3ThromboGenics N.V.: Business Update 4ThromboGenics N.V.: Business Update 5ThromboGenics N.V.: Business Update 6ThromboGenics N.V.: Business Update 7ThromboGenics N.V.: Business Update 8AmeriCares Presents 'Power of Partnership' Award to Baxter 2AmeriCares Presents 'Power of Partnership' Award to Baxter 3AMDL, Inc. New President & CEO Douglas MacLellan to Present at Rodman & Renshaw Annual Global Investment Conference November 12, 2008 2
(Date:2/19/2015)... Feb .19, 2015 Research and Markets ... of the "Military Electro-Optical / Infrared Systems ... by Platform - Forecast to 2020" report ... electro-optical/infrared systems market is expected to reach $16.35 ... 7.71%. This report segments the military ...
(Date:2/11/2015)... DALLAS , February 11, 2015 /PRNewswire/ ... market research report "Access Control Market by Product ... (Commercial, Residential, Military and Defense, Government, Industrial, Healthcare, ... , published by MarketsandMarkets, the Access Control ... by 2020, growing at a CAGR of ...
(Date:2/5/2015)... Epic Sciences , a precision diagnostics company dedicated to improving ... , Ph.D., president and CEO, is scheduled to present at ... Valley, which is taking place at the Computer History Museum ... 26-28, 2015. Dr. Prahalad will give a ... Epic Sciences was a finalist in the PMWC,s Most Promising ...
Breaking Biology News(10 mins):Military Electro-Optical / Infrared Systems (Image Intensification, Laser, Infrared) Market - Forecast to 2020: Featuring Profiles of the Market Leaders on this $16 Billion market 2Military Electro-Optical / Infrared Systems (Image Intensification, Laser, Infrared) Market - Forecast to 2020: Featuring Profiles of the Market Leaders on this $16 Billion market 3Access Control Market Worth $10.4 Billion by 2020 2Access Control Market Worth $10.4 Billion by 2020 3Access Control Market Worth $10.4 Billion by 2020 4Epic Sciences to Present at Personalized Medicine World Conference 2015 on the Use of Circulating Tumor Cells as Cancer Biomarkers 2
... Dr. Jian Han, faculty investigator at the HudsonAlpha ... response, molecular-level assay for swine flu, the current strain ... test, which can confirm swine flu in less than ... panel made available by Diatherix Laboratories. The panel ...
... but on the riseand infants are the most common ... aims to raise awareness of this often overlooked crime. ... of Pharmacy, and recent graduate Brian Ferslew examined seven ... deaths due to homicidal poisoninga figure that corresponds to ...
... University researchers, along with scientists at Washington University in ... by studying the brain while it is at rest. ... new tools for diagnosing mental health disorders and monitoring ... published in the journal the Public Library of ...
Cached Biology News:HudsonAlpha investigator develops rapid response swine flu test 2Study finds homicidal poisoning rising, more likely in infants and elderly 2OHSU researchers study the idling brain 2
Leptin Receptor Polyclonal Ab 100 ug purified rabbit anti-mouse Leptin Receptor. Tested in Western blotting....
... AccuPrime™ Pfx DNA Polymerase is ... fragments for downstream applications such as ... is provided by a proprietary enzyme ... Pyrococcus sp. with proofreading (3'Cut Site5' ...
... amino acid polypeptide sequence corresponding to Tyr89 ... Produced by activation of a recombinant soluble ... periplasm. SPECIFIC ACTIVITY:The specific activity of ... where 1 U is the activity that ...
... Grade Thrombin is a highly purified preparation ... with appropriate vectors. The preparation is functionally ... is free of detectable contaminating proteases. Prepared ... by certified tests to be negative for ...
Biology Products: